Type 1 Diabetes Mellitus: A Review on Advances and Challenges in Creating Insulin Producing Devices
Open Access
- 6 January 2023
- journal article
- review article
- Published by MDPI AG in Micromachines
- Vol. 14 (1) , 151
Abstract
Type 1 diabetes mellitus (T1DM) is the most common autoimmune chronic disease in young patients. It is caused by the destruction of pancreatic endocrine β-cells that produce insulin in specific areas of the pancreas, known as islets of Langerhans. As a result, the body becomes insulin deficient and hyperglycemic. Complications associated with diabetes are life-threatening and the current standard of care for T1DM consists still of insulin injections. Lifesaving, exogenous insulin replacement is a chronic and costly burden of care for diabetic patients. Alternative therapeutic options have been the focus in these fields. Advances in molecular biology technologies and in microfabrication have enabled promising new therapeutic options. For example, islet transplantation has emerged as an effective treatment to restore the normal regulation of blood glucose in patients with T1DM. However, this technique has been hampered by obstacles, such as limited islet availability, extensive islet apoptosis, and poor islet vascular engraftment. Many of these unsolved issues need to be addressed before a potential cure for T1DM can be a possibility. New technologies like organ-on-a-chip platforms (OoC), multiplexed assessment tools and emergent stem cell approaches promise to enhance therapeutic outcomes. This review will introduce the disorder of type 1 diabetes mellitus, an overview of advances and challenges in the areas of microfluidic devices, monitoring tools, and prominent use of stem cells, and how they can be linked together to create a viable model for the T1DM treatment. Microfluidic devices like OoC platforms can establish a crucial platform for pathophysiological and pharmacological studies as they recreate the pancreatic environment. Stem cell use opens the possibility to hypothetically generate a limitless number of functional pancreatic cells. Additionally, the integration of stem cells into OoC models may allow personalized or patient-specific therapies.Keywords
Funding Information
- project CICECO-Aveiro Institute of Materials (UIDB/50011/2020, UIDP/50011/2020, LA/P/0006/2020)
This publication has 166 references indexed in Scilit:
- Environmental Triggers of Type 1 DiabetesCold Spring Harbor Perspectives in Medicine, 2012
- The use of animal models in diabetes researchBritish Journal of Pharmacology, 2012
- Dynamic monitoring of glucagon secretion from living cells on a microfluidic chipAnalytical and Bioanalytical Chemistry, 2012
- Antigen Targets of Type 1 Diabetes AutoimmunityCold Spring Harbor Perspectives in Medicine, 2012
- Epidemiology of Type 1 DiabetesEndocrinology and Metabolism Clinics of North America, 2010
- Human Induced Pluripotent Stem Cells Develop Teratoma More Efficiently and Faster Than Human Embryonic Stem Cells Regardless the Site of InjectionStem Cells, 2010
- Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model DiseaseCell Stem Cell, 2009
- Quantitative Monitoring of Insulin Secretion from Single Islets of Langerhans in Parallel on a Microfluidic ChipAnalytical Chemistry, 2009
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Translational Mini-Review Series on Type 1 Diabetes: Systematic analysis of T cell epitopes in autoimmune diabetesClinical and Experimental Immunology, 2007